A mobile app for the treatment of female mixed and urgency incontinence: a cost-effectiveness analysis in Sweden.

Introduction And Hypothesis: A previous randomized controlled trial (RCT) demonstrated that the app Tät II, for self-management of mixed urinary incontinence (MUI) and urgency urinary incontinence (UUI), yielded significant, clinically relevant improvements in symptom severity and quality of life (QoL) compared with a control group. We aimed to assess the cost-effectiveness of Tät II.

Methods: A cost-utility analysis with a 1-year societal perspective was carried out, comparing Tät II with an information app.